Elevated levels of COX-2 and its metabolites, such as PGE2, an inflammatory mediator, have been associated with aggressive breast cancer phenotypes and poor survival (13, 30, 31), whereas inhibition of COX-2 activity has shown anti-tumor and therapeutic effects in preclinical models and population studies (12, 32–35). This evidence concerns the gene PTGS2 and breast cancer.